Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

Authors

Brian Schulte, Northwestern University
Nisha Mohindra, Northwestern University
Mohammed Milhem, University of Iowa
Steven Attia, Mayo Clinic
Steven Robinson, Mayo Clinic
Varun Monga, University of Iowa
Angela C Hirbe, Washington University School of Medicine in St. Louis
Peter Oppelt, Washington University School of Medicine in St. Louis
John Charlson, Medical College of Wisconsin
Irene Helenowski, Northwestern University
Susan Abbinanti, Northwestern University
Rasima Cehic, Northwestern University
Scott Okuno, Mayo Clinic
Brian A Van Tine, Washington University School of Medicine in St. Louis
Mark Agulnik, Northwestern University

Journal

British Journal of Cancer

Publication Date

2021

Document Type

Open Access Publication

DOI

10.1038/s41416-021-01448-0

Rights and Permissions

Schulte B, Mohindra N, Milhem M, et al. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas [published online ahead of print, 2021 May 28]. Br J Cancer. 2021;10.1038/s41416-021-01448-0. doi:10.1038/s41416-021-01448-0. https://www.nature.com/bjc/

Recommended Citation

Schulte, Brian; Mohindra, Nisha; Milhem, Mohammed; Attia, Steven; Robinson, Steven; Monga, Varun; Hirbe, Angela C; Oppelt, Peter; Charlson, John; Helenowski, Irene; Abbinanti, Susan; Cehic, Rasima; Okuno, Scott; Van Tine, Brian A; and Agulnik, Mark, "Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas." British Journal of Cancer. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10375